A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers
An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Queensland
-
Brisbane, Queensland, Australia, 4006
- Q-Pharm
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy males and females aged 18 years to less than 55 years
- Body weight 50kg or greater
- Body mass index (BMI) between 18 and 42.0 kg/m2
Exclusion Criteria:
- Evidence of a clinically significant medical condition, disorder or disease
- Evidence of hepatobiliary disease
- Any clinically relevant abnormal laboratory test result
- Evidence or history of alcohol or substance abuse
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: CSL112
Multiple ascending intravenous doses of CSL112
|
reconstituted high density lipoprotein
|
|
Placebo Comparator: Placebo
Multiple intravenous infusions of placebo
|
Normal saline (0.9%)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The frequency of drug-related adverse events
Time Frame: Up to 6 days after each infusion
|
Up to 6 days after each infusion
|
|
The frequency of redness and swelling at the infusion site
Time Frame: up to 24 hours after each infusion
|
up to 24 hours after each infusion
|
|
Clinically important elevation of alanine aminotransferase (ALT) or aspartate aminotransferase (AST)
Time Frame: up to 6 days after each infusion
|
up to 6 days after each infusion
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Pharmacokinetic profile of apoA-I after multiple intravenous infusions
Time Frame: up to 7 days after each infusion
|
up to 7 days after each infusion
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Senior Director, Cardiovascular, CSL Limited
Publications and helpful links
General Publications
- Zheng B, Duffy D, Tricoci P, Kastrissios H, Pfister M, Wright SD, Gille A, Tortorici MA. Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A-I and cholesterol efflux capacity in acute myocardial infarction patients. Br J Clin Pharmacol. 2021 Jun;87(6):2558-2571. doi: 10.1111/bcp.14666. Epub 2020 Dec 23.
- Easton R, Gille A, D'Andrea D, Davis R, Wright SD, Shear C. A multiple ascending dose study of CSL112, an infused formulation of ApoA-I. J Clin Pharmacol. 2014 Mar;54(3):301-10. doi: 10.1002/jcph.194. Epub 2013 Oct 22.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- CSLCT-HDL-10-68
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.